Drug intelligence / Profile preview

KMV002

Development stage: Preclinical
Lead developer: Chimigen Biosciences
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

KMV002 (also known as IPT-PAP) is an investigational immunotherapy being developed by Chimigen Biosciences for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Utilizing the proprietary SynNeogen® platform, KMV002 is an engineered Fc-fusion protein designed for Immune Priming Therapy (IPT). It functions by delivering multi-epitope prostatic acid phosphatase (PAP) payloads directly to dendritic cells, which facilitates efficient antigen presentation and the priming of both CD4+ and CD8+ T cells. This mechanism is intended to reverse immune tolerance and transform immunologically "cold" tumors into an immune-responsive state, potentially enhancing the therapeutic effects of immune checkpoint inhibitors, androgen receptor-targeted drugs, and radiation therapy. As of 2024, the drug is in the IND-enabling phase of development.

Other names: IPT-PAP

Targets

PAP (Prostatic acid phosphatase)

Beyond the preview

Go deeper on KMV002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KMV002.

Explore the full profile